Supreme Court Reinstated Mail-Order Access to Mifepristone After Appeals Court Restriction
Initially, the 5th U. S. Circuit Court of Appeals ruled that the abortion pill mifepristone must be dispensed in person at clinics, effectively blocking its distribution by mail and restricting nationwide access. This decision overrode existing FDA regulations that allowed mail and telehealth distribution, prompting drugmakers Danco Laboratories and GenBioPro to petition the U. S.
Supreme Court to overturn the ruling. Subsequently, the U. S. Supreme Court issued a temporary stay reinstating the ability to obtain mifepristone via mail, telehealth, and pharmacies pending further legal review. Justice Samuel Alito specifically granted this temporary relief, allowing mail-order access to resume at least until the Supreme Court completes its review, thereby maintaining broader access to the abortion pill during the interim period.
